Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Clinical Trials, Phase I as Topic
  • Nomograms

abstract

  • This nomogram can be used to accurately predict a patient's risk for SDRT at the time of enrollment. Excluding patients at high risk for SDRT should improve the safety and efficiency of phase I trials.

publication date

  • February 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3918535

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.49.8808

PubMed ID

  • 24419130

Additional Document Info

start page

  • 519

end page

  • 26

volume

  • 32

number

  • 6